ANNA is particularly looking for novel medicines against cancer, diseases related to the immune system and infections. 

ANNA aims to develop natural novel, biobased medicines, which can hardly be patented. A drugcandidate covered by a (fully owned) patent doesn't raise its chances to be a succesfull drugcandidate. ANNA aims to cover its strategic position by obtaining licence agreements, from companies which possess patents in the field of nanocarriers.  

ANNA considers the best possible nanocarriers, as those which deliver the particular drugcandidates, at the disease affected tissues. If such can be achieved and the effects are leading to a serious improved situation for the patients, ANNA considers such already as  a major achievement. So 'the best nanocarriers' is considered to be a subjective point of view.

ANNA solely works with GMP certified producers of purified natural drugcandidates.

Currently ANNA has no drugcandidates in clinical trials. As soon as ANNA will initiate Clinical Trials, we will post it in our pipeline-section of the website.

ANNA aims to sign strategic partnerships with major Pharmaceutical companies. Such partnerships should lead to a substantial stream of revenues.

ANNA is a privately held company and its shares are not publicly traded. ANNA is open to talks with potential investors and or strategic partners.